News and Trends 14 Nov 2022 A biotech boom manifesting real results in rare pediatric diseases By Bob Coughlin, managing director, life sciences, JLL For the last two years, the pandemic has resulted in the explosive growth in life sciences. The world watched in awe and anticipation as biotech successfully raced to develop vaccines, therapeutics and diagnostics for Covid-19. It has been a good moment for an industry that deserves such […] November 14, 2022 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 14 Nov 2022 Researchers discover protein facilitates relapse of pediatric brain tumors The malignant brain tumor type medulloblastoma can become resistant to therapy, which can cause relapse. Researchers at Uppsala University in Sweden have discovered a protein that makes tumor cells insensitive to radiation treatment. The scientists hope the results could lead to better treatments for children with the highest risk to develop relapses. Avoiding treatment Medulloblastoma […] November 14, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Nov 2022 Prurigo nodularis treatment recommended for EU approval The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the approval of Dupixent (dupilumab) in the European Union (EU) to treat adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy. Dupilumab is being jointly developed by Sanofi and Regeneron. The European Commission is expected […] November 11, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Nov 2022 PACT Pharma reports data from CRISPR cancer study PACT Pharma, Inc. has reported data from the first clinical study using CRISPR gene editing technology to substitute a gene in patients’ immune cells to treat cancer. Results from the study, which was conducted with collaborators at nine academic centers using PACT Pharma’s platforms, demonstrated early proof-of-concept that a patient’s immune system can be reprogrammed […] November 11, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Nov 2022 Program management support: accelerating growth for early stage biotechs More academic groups, new start-ups, biotechs and small pharma companies are turning to external consultants for professional program management support and guidance to help them progress their ideas into medicines for patients. Ian Hollingsworth, associate director of product development at Boyds, a global drug development consultancy, explains the common reasons why academic spinouts and small […] November 11, 2022 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 11 Nov 2022Beyond Biotech podcast 22: PacBio, Sierra Space This week, we have two longer interviews. We have conversations with Neil Ward, VP of PacBio EMEA, and Marc Giulianotti, senior manager in space biomanufacturing at Sierra Space. We also have our weekly contribution from global commercial real estate services company JLL, with Travis McCready. Sierra Space and UC San Diego to develop first stem […] November 11, 2022 Share WhatsApp Twitter Linkedin Email
News and Trends 10 Nov 2022 SOTIO reveal potential treatment for adults with solid tumors at SITC meeting SOTIO Biotech has presented preclinical results of its BOXR T cell therapy platform and revealed it indicates a strong clinical path for its first transgene-expressing CAR-T cell as a potential treatment for solid tumors in adults with cancer. The results were presented at the Society for Immunotherapy of Cancer’s (SITC) 37th annual meeting taking place […] November 10, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 10 Nov 2022 Parthenon and ImaginAb enter into license and supply agreement for anti-cancer therapies Precision oncology company, Parthenon Therapeutics, and ImaginAb Inc., a global biotech have entered into a multi-year, non-exclusive license and supply agreement. Under the agreement terms, Parthenon will use ImaginAb’s CD8 ImmunoPET imaging technology in its phase 1 trial evaluating its lead compound, PRTH-101, which is expected to begin in 2023. ImaginAb is developing 89Zr crefmirlimab […] November 10, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 10 Nov 2022 Sanofi and GSK Covid-19 booster vaccine approved by European Commission Sanofi and GSK’s Covid booster vaccine has been approved in Europe. After the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn Beta, the vaccine was approved by the European Commission, as a booster for the prevention of Covid-19 in adults 18 years of age and older. […] November 10, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 10 Nov 2022 Promising drug candidate discovered for prevention of type 1 diabetes According to a new study in Finland, type 1 diabetes could be prevented by inhibiting a gene associated with the onset of the disease. A drug based on the same mechanism has already been approved for the treatment of another autoimmune disease, psoriasis, in the U.S., which may boost the development of drug therapies for […] November 10, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Startup Scout 10 Nov 2022 ResQ Biotech is using bacteria to discover Alzheimer’s treatments Protein misfolding underlies many incurable conditions such as Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). The Greek startup ResQ Biotech is harnessing bacteria to test potential peptide treatments for these diseases. There are many diseases that involve the faulty processing of proteins in the cell, leading the proteins to clump together and damage the tissue. […] November 10, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 10 Nov 2022 Eye disease therapies being developed after Breye Therapeutics’ €4M seed financing Breye Therapeutics ApS a biopharmaceutical company developing therapies for retinal vascular diseases today (November 10) has closed a seed financing of €4 million led by Novo Holdings and Sound Bioventures. Diabetic retinopathy (DR) affects approximately 30% of all patients with diabetes and is the leading cause of blindness among working-age adults. Age-related macular degeneration (AMD) […] November 10, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email